Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell Transplantation
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Antivirals such as valganciclovir act against viruses and may be effective in
preventing cytomegalovirus. It is not yet known if valganciclovir is effective in preventing
cytomegalovirus.
PURPOSE: This randomized phase III trial is studying valganciclovir to see how well it works
in preventing cytomegalovirus in patients who have undergone donor stem cell transplantation.